@article{8ec1696f31ac453fa52ccb5a2bd17660,
title = "FIGHT against FGF/FGFR alterations: what are the next steps?",
author = "A. Bayle and P. Martin-Romano and Y. Loriot",
note = "Funding Information: None declared. YL: consulting or advisory Role: Janssen, Janssen (Inst), Astellas, Roche, AstraZeneca, Merck & Co. Kenilworth, NJ, Seattle Genetics, Bristol Myers Squibb, Immunomedics, and Taiho Pharmaceutical; travel, accommodation, expenses: Astellas, Janssen, Roche, Merck & Co. Kenilworth, NJ, AstraZeneca, and Seattle Genetics; honoraria: Sanofi and Pfizer; research funding: Sanofi (Inst), Janssen Oncology (Inst), Merck & Co. Kenilworth, NJ (Inst), AstraZeneca (Inst), Clovis Oncology (Inst), Celsius (Inst), Exelixis (Inst), Incyte (Inst), Pfizer (Inst), and Nektar (Inst). All other authors have declared no conflicts of interest.",
year = "2022",
month = may,
day = "1",
doi = "10.1016/j.annonc.2022.03.014",
language = "English",
volume = "33",
pages = "460--462",
journal = "Annals of Oncology",
issn = "0923-7534",
number = "5",
}